TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
Taiwan · Delayed Price · Currency is TWD 7.93
-0.17 (-2.10%)
Jul 29, 2026, 1:30 PM CST
TPEX:4157 Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 258.93 | 259.47 | 150.65 | 123.13 | 36.23 | 1,295 |
Revenue Growth | 70.95% | 72.23% | 22.35% | 239.87% | -97.20% | 5426.95% |
Gross Profit Gross Profit Growth | 241.77 | 241.3 | 134.52 | 111.69 | 32.49 | 1,282 |
Operating Income Operating Income Growth | 75.49 | 69.4 | -122.1 | -174.7 | -277.67 | 899.46 |
Net Income Net Income Growth | 53.51 | 45.18 | -38.58 | 136.73 | -237.16 | 775.62 |
Earnings Per Share EPS Growth | 0.07 | 0.06 | -0.05 | 0.19 | -0.33 | 1.08 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Research and Development of New Drugs Research and Development of New Drugs Growth | 258.84 | 259.42 | 149.15 | 119.15 | 36.23 | 1,295 |
The Others The Others Growth | - | 0.06 | 1.5 | 3.99 | - | - |
Total Total Growth | 258.93 | 259.47 | 150.65 | 123.13 | 36.23 | 1,295 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 960.94 | 1,027 | 1,020 | 1,038 | 898.6 | 924.4 |
Total Debt Total Debt Growth | 12.83 | 49.22 | 58.71 | 74.69 | 38.47 | 53.46 |
Net Cash (Debt) Net Cash Growth | 948.11 | 977.54 | 961.11 | 963.3 | 860.13 | 870.94 |
Net Cash Growth | 2.05% | 1.71% | -0.23% | 12.00% | -1.24% | 177.67% |
Net Cash Per Share Net Cash Per Share Growth | 1.33 | 1.37 | 1.34 | 1.34 | 1.20 | 1.21 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 64.82 | 20.93 | -173.09 | 7.46 | -21.27 | 629.07 |
Capital Expenditures CapEx Growth | -1.55 | -1.45 | -0.53 | -3.89 | -3.39 | -10.24 |
Free Cash Flow Free Cash Flow Growth | 63.27 | 19.48 | -173.62 | 3.57 | -24.66 | 618.83 |
Free Cash Flow Growth | -44.21% | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 93.37% | 93.00% | 89.29% | 90.70% | 89.69% | 99.02% |
Operating Margin | 29.16% | 26.74% | -81.05% | -141.88% | -766.41% | 69.48% |
Pretax Margin | 25.64% | 22.14% | -21.83% | 116.53% | -634.18% | 67.67% |
Profit Margin | 20.66% | 17.41% | -25.61% | 111.04% | -654.61% | 59.91% |
FCF Margin | 24.43% | 7.51% | -115.25% | 2.90% | -68.06% | 47.80% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 112.75 | 211.13 | - | 79.80 | - | 14.23 |
Forward PE | - | 27.83 | 27.83 | 27.83 | 27.83 | 27.83 |
P/FCF Ratio | 89.22 | 489.64 | - | 3055.51 | - | 17.84 |
PS Ratio | 21.80 | 36.76 | 54.56 | 88.61 | 317.56 | 8.53 |